Filings & corporate actions
- 31 JulresultsResults · Q1 FY27 · consolidated and standalone+0.3%NSE
- 13 JulshareholdingShareholding · 30 Jun 2026+0.6%NSE
- 19 JundividendDividend · ₹10.00 per share+1.8%
- 11 MayresultsResults · Q4 FY26 · consolidated and standalone-7.1%NSE
- 17 AprshareholdingShareholding · 31 Mar 2026+2.8%NSE
- 2 FebresultsResults · Q3 FY26 · consolidated and standalone+2.9%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-3.1%NSE
- 5 JanresultsResults · Q2 FY26 · consolidated and standalone+1.6%NSE
Reaction to results · all yearsrose on day 0 in 3 of 4 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 31 Jul 2026 | +0.3% | -0.8% | -2.3% | 4.4× |
| Q4 FY26 | 11 May 2026 | -7.1% | +1.5% | -1.2% | 9.4× |
| Q3 FY26 | 2 Feb 2026 | +2.9% | +11.9% | +5.9% | 0.6× |
| Q2 FY26 | 5 Jan 2026 | +1.6% | -3.0% | +4.0% | — |
| Average | -0.6% | +2.4% | +1.6% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSV| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVDelivery percentage
Over the last 20 sessions CORONA settled 48.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 46.0%, so recent sessions are running 2.5 points higher than usual.
What delivery percentage measuresScan the whole market on delivery
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.20% | -0.73% | -4.21% | +2.49% | +35.96% | — |
Valuation
CSVOwnership
CSVQuarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 361.1 | 342.4 | 353.1 | 422.4 |
| YoY chg | — | — | — | — |
| Net profit (₹ Cr) | 52.3 | 41.3 | 45.3 | 60.1 |
| YoY chg | — | — | — | — |
| Net margin | 14.5% | 12.1% | 12.8% | 14.2% |
| EPS | 8.55 | 6.75 | 7.41 | 9.83 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 69.00% · public 31.00%- Promoter
- Public and others
- Promoter
- 69.00%
- Public
- 31.00%
- Promoter change
- 0.00 pp
- Filed
- 13 Jul 2026
- FII
- 3.63%
- DII
- 12.90%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|
| Revenue from operations | 361.1 | 342.4 | 353.1 | 422.4 | |
| Other income | 2.3 | 2.2 | 4.1 | 3.2 | |
| Total income | 363.4 | 344.7 | 357.2 | 425.6 | |
| Total expenses | 293.8 | 270.4 | 302.7 | 345.2 | |
| └ Finance costs | 1.9 | 1.7 | 1.4 | 2.7 | |
| └ Depreciation | 9.2 | 9.5 | 10.3 | 13.2 | |
| Profit before tax | 69.6 | 55.2 | 54.7 | 80.4 | |
| Tax expense | 17.5 | 13.9 | 9.4 | 20.3 | |
| Net profit | 52.3 | 41.3 | 45.3 | 60.1 | |
| EPS | 8.55 | 6.75 | 7.41 | 9.83 | |
| Net margin | 14.49% | 12.05% | 12.84% | 14.23% | |
| PBT margin | 19.28% | 16.12% | 15.50% | 19.02% | |
| Tax rate | 25.08% | 25.25% | 17.19% | 25.20% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 31 Jul 2026.
4 quarters on file; a year-on-year comparison needs five.
CORONA at a glance
- CORONA closed at ₹2,038.3 on 6 Oct 2026, +0.20% on the day.
- Delivery was 58.8% of traded quantity on 6 Oct 2026, the 86th percentile of its own 200 sessions with a reading (20-session average 48.6%, 1-year average 46.0%).
- Market capitalisation is ₹12,466 crore at a trailing P/E of 62.6 (trailing EPS ₹32.54).
- Q1 FY27 results (consolidated, filed 31 Jul 2026): revenue ₹422 crore, net profit ₹60 crore; the price moved +0.3% on the first session after.
- Promoters held 69.00% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 31 Oct 2026 and 5 Jan 2027, going by past filing dates — an estimate, not an announcement.
About
CSVPrices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE